This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Age 18-55 years old
* Must be in good health with no significant medical history
* BMI 18-35 kg/m2
* Contraceptive use consistent with local regulations
* Able and willing to provide written informed consent
Exclusion Criteria:
* Any physical condition that prohibits study completion
* Known hypersensitivity to the trial intervention or any of its components
* HIV, hepatitis B and hepatitis C positive
* Clinically significant abnormal ECG
* Use of other investigational products within 5 half lives from Screening
* Blood or plasma donation within 60 days from Screening
* Pregnant or breastfeeding
Other protocol defined inclusion/exclusion criteria apply
Primary outcome measure(s)
Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb412 in healthy adult participants (Part A and Part B) — Up to 28 weeks
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.